NVS.US Novartis AG ADR

Healthcare Pharmaceuticals USA Stocks
160.50 USD
Close of Nov 15, 2026
119.60 165.96
Market cap
USD 303B
P/E
30.6x
P/B
8.14x
ROE
27.3%
Dividend yield
2.58%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is NVS.US undervalued?

Graham number

The Graham number of Novartis AG ADR cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Novartis AG ADR fundamental analysis

No fundamental analysis for Novartis AG ADR yet.

Novartis AG ADR stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Novartis AG ADR

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade fo…

Full company profile